bluebird bio to be Acquired
- Posted by ISPE Boston
- On March 20, 2025
bluebird bio has entered into a definitive agreement to be acquired by private-equity firms Carlyle Group and SK Capital Partners in collaboration with a team of highly experienced biotech executives in a deal worth up to $96 million. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will […]
Read More